Press Release
Media
Share Our Bit by
Bit With You
Bit With You
-
January 18 2022ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety dataLearn More
SHENZHEN, China, Jan. 18, 2022 /PRNewswire/ -- ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical study, and demonstrated good safety and tolerability results.
-
August 08 2021ImmVira's MVR-C5252 Targeting Brain Tumor Obtained US FDA's Approval for Clinical TrialLearn More
SHENZHEN, China, Aug. 8, 2021 /PRNewswire/ -- ImmVira announces MVR-C5252 targeting Glioblastoma has received the U.S. FDA clearance to proceed with clinical trial on August 6, 2021.
-
August 08 2021ImmVira's MVR-C5252 Targeting Brain Tumor Obtained US FDA's Approval for Clinical TrialLearn More
SHENZHEN, China, Aug. 8, 2021 /PRNewswire/ -- ImmVira announces MVR-C5252 targeting Glioblastoma has received the U.S. FDA clearance to proceed with clinical trial on August 6, 2021.
-
August 06 2021ImmVira's MVR-T3011 Obtained NMPA's Approval for Intravenous Administration (IV) Phase I Clinical TrialLearn More
SHENZHEN, China, Aug. 6, 2021 /PRNewswire/ -- ImmVira announced that as a global first, its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011), obtained approval from National Medical Products Administration ("NMPA") for clinical trial for treatments using intravenous administration (IV) on August 6, 2021.
-
June 11 2021ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and ChinaLearn More
SHENZHEN, China, June 11, 2021 /PRNewswire/ -- ImmVira announced that in the Phase II Clinical Trials of its leading oncolytic virus product, MVR-T3011* as intratumoral administration (MVR-T3011 IT), ImmVira has completed the first dosing in both China and the U.S. on May 28 2021 and June 11 2021, respectively.
-
June 02 2021ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021Learn More
SHENZHEN, China, June 2, 2021 /PRNewswire/ -- ImmVira will present results from its clinical Phase I study of MVR-T3011 via intratumoral (IT) administration at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8, 2021 for the first time.
